Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Admission Predictors of Mortality in Hospitalized COVID-19 Patients-A Serbian Cohort Study.
Poskurica M, Stevanović Đ, Zdravković V, Čekerevac I, Ćupurdija V, Zdravković N, Nikolić T, Marković M, Jovanović M, Popović M, Vesić K, Azanjac Arsić A, Lazarević S, Jevtović A, Patrnogić A, Anđelković M, Petrović M. Poskurica M, et al. Among authors: petrovic m. J Clin Med. 2022 Oct 17;11(20):6109. doi: 10.3390/jcm11206109. J Clin Med. 2022. PMID: 36294430 Free PMC article.
Anthropometric Measurements and Admission Parameters as Predictors of Acute Respiratory Distress Syndrome in Hospitalized COVID-19 Patients.
Zdravković V, Stevanović Đ, Ćićarić N, Zdravković N, Čekerevac I, Poskurica M, Simić I, Stojić V, Nikolić T, Marković M, Popović M, Divjak A, Todorović D, Petrović M. Zdravković V, et al. Among authors: petrovic m. Biomedicines. 2023 Apr 18;11(4):1199. doi: 10.3390/biomedicines11041199. Biomedicines. 2023. PMID: 37189817 Free PMC article.
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.
Andric Z, Gálffy G, Cobo Dols M, Szima B, Stojanovic G, Petrovic M, Felip E, Vicente Baz D, Ponce Aix S, Juan-Vidal O, Szalai Z, Losonczy G, Calles Blanco A, Bernabe R, García Ledo G, Aguilar Hernández A, Duecker K, Zhou D, Schroeder A, Guezel G, Ciardiello F. Andric Z, et al. Among authors: petrovic m. JTO Clin Res Rep. 2023 Jan 2;4(2):100461. doi: 10.1016/j.jtocrr.2022.100461. eCollection 2023 Feb. JTO Clin Res Rep. 2023. PMID: 36718142 Free PMC article.
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Trukhin D, Poddubskaya E, Andric Z, Makharadze T, Bellala RS, Charoentum C, Yañez Ruiz EP, Fulop A, Hyder Ali IA, Syrigos K, Katgi N, Lopez Chuken YA, Rumyana I, Reyes-Igama J, Costamilan RC, Del Campo García A, Florez A, Paravisini A, Millan S; STELLA Investigators. Trukhin D, et al. BioDrugs. 2021 Jul;35(4):429-444. doi: 10.1007/s40259-021-00483-w. Epub 2021 Apr 29. BioDrugs. 2021. PMID: 33914256 Free PMC article. Clinical Trial.
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA; RESILIENT Trial Investigators. Spigel DR, et al. J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110. Online ahead of print. J Clin Oncol. 2024. PMID: 38648575
1,424 results